Dive Brief:

潜水简介：

An experimental cancer drug developed by Revolution Medicines shrank pancreatic tumors in about one-quarter of participants who had been followed for at least five months after treatment in an early-stage study.

Revolution Medicines开发的一种实验性抗癌药物在一项早期研究中治疗后至少五个月，约四分之一的参与者的胰腺肿瘤缩小。

The update, which Revolution Medicines shared with investors Monday, is the latest cut of data from the trial, which has tested the company’s targeted therapy RMC-6236 in people with lung or pancreatic tumors that are driven to growth by mutations in a cancer gene known as RAS.

Revolution Medicines周一与投资者分享的最新数据是该试验的最新数据，该试验测试了该公司针对肺癌或胰腺肿瘤患者的靶向治疗RMC-6236，这些肿瘤是由称为RAS的癌症基因突变驱动的。

Among study participants who previously received one or more prior drug regimens for their cancer and have a “KRAS G12X” mutation, treatment with RMC-6236 led to a median progression-free survival of 8.1 months. Revolution claims this is higher than typically seen with other regimens and is advancing its drug into a Phase 3 pancreatic cancer trial later this year..

在先前接受过一种或多种癌症药物治疗且具有“KRAS G12X”突变的研究参与者中，使用RMC-6236治疗的中位无进展生存期为8.1个月。Revolution声称这比其他方案通常看到的要高，并将其药物推进今年晚些时候的3期胰腺癌试验。。

Dive Insight:

潜水洞察：

Revolution Medicines is one of a handful of biotechnology and pharmaceutical firms looking to exploit drug research advances that have made RAS mutations easier to target. Mutations in the gene are frequently a trigger for cancers of the lungs, pancreas or colon.

Revolution Medicines是少数几家寻求利用药物研究进展的生物技术和制药公司之一，这些进展使RAS突变更容易靶向。基因突变通常是肺癌、胰腺癌或结肠癌的诱因。

Pancreatic cancer, which is considered among the hardest tumor types to treat, is particularly dependent on RAS mutations, according to Revolution Medicines. Currently, however, standard treatment is chemotherapy-based regimens that have limited effectiveness.

据Revolution Medicines称，胰腺癌被认为是最难治疗的肿瘤类型之一，它特别依赖于RAS突变。然而，目前，标准治疗是基于化疗的方案，效果有限。

RMC-6236 is designed to inhibit RAS signaling by binding to the mutant protein in its “on” state. The company’s first-in-human study, which has enrolled nearly 400 patients with RAS-driven solid tumors, has so far evaluated nine different doses of the drug. Results were last presented in October.

RMC-6236旨在通过与处于“开启”状态的突变蛋白结合来抑制RAS信号传导。该公司的第一项人体研究已经招募了近400名RAS驱动的实体瘤患者，迄今为止已经评估了9种不同剂量的药物。最后一次公布结果是在10月份。

Monday’s data are from 127 study participants with pancreatic ductal carcinoma who received between 160 milligram and 300 milligram doses of RMC-6236. Nearly all experienced side effects, most commonly rash, diarrhea, mouth sores and vomiting. Those adverse events were considered severe or medically significant in 22% of participants and in 28% required dose modification..

周一的数据来自127名胰腺导管癌研究参与者，他们接受了160毫克至300毫克剂量的RMC-6236。几乎所有患者都有副作用，最常见的是皮疹、腹泻、口腔溃疡和呕吐。这些不良事件在22%的参与者中被认为是严重的或具有医学意义的，28%的参与者需要调整剂量。。

Median progression-free survival, a measure of how long treatment staves off disease progression or death, was a median of 8.1 months in people who specifically have the KRAS G12X mutation, and 7.6 months in those who broadly have RAS mutant tumors, including those with KRAS G12X changes. According to Revolution Medicines, the benchmark median progression-free survival for chemotherapy regimens in this setting ranges from 2 months to 3.5 months..

中位无进展生存期是衡量治疗延缓疾病进展或死亡时间的指标，特别是KRAS G12X突变患者的中位生存期为8.1个月，广泛患有RAS突变肿瘤（包括KRAS G12X突变患者）的中位生存期为7.6个月。根据Revolution Medicines的数据，在这种情况下，化疗方案的基准中位无进展生存期为2个月至3.5个月。。

Among participants who had at least three prior treatment regimens, the median progression-free survival was 4.2 months.

在至少有三种先前治疗方案的参与者中，中位无进展生存期为4.2个月。

Revolution Medicines said it plans to advance the 300 milligram dose of RMC-6236 into a Phase 3 study comparing it to investigator’s choice of standard chemo among previously treated people with pancreatic cancer. The company anticipates starting the study in the second half of the year, with progression-free survival data coming in the first half of 2026..

Revolution Medicines表示，计划将300毫克剂量的RMC-6236推进第三阶段研究，将其与研究者在先前接受治疗的胰腺癌患者中选择的标准化疗进行比较。该公司预计将在今年下半年开始这项研究，2026年上半年将公布无进展生存数据。。

Along with Revolution Medicines, a range of other companies are advancing RAS inhibitors in solid tumors, including BridgeBio Oncology Therapeutics, Frontier Medicines and Eli Lilly. Two drugs specifically targeted to KRAS mutations, Amgen’s Lumakras and Bristol Myers Squibb’s Krazati, are currently approved for lung cancer..

与Revolution Medicines一起，一系列其他公司正在推进实体瘤中的RAS抑制剂，包括BridgeBio Oncology Therapeutics，Frontier Medicines和Eli Lilly。两种专门针对KRAS突变的药物，安进的Lumakras和百时美施贵宝的Krazati，目前已被批准用于肺癌。。

Revolution Medicines recently absorbed EQRx via an all-stock deal, swelling its cash balance to $1.7 billion as of March 31. Shares in the company fell in early Monday morning trading before bouncing back to trade up by more than 2%.

Revolution Medicines最近通过全股票交易吸收了EQRx，截至3月31日，其现金余额增至17亿美元。该公司股票在周一早上的交易中下跌，随后反弹，交易量上涨了2%以上。